Published On: Wed, Oct 19th, 2016

MannKind Corporation (MNKD) Latest Broker Coverage


A number of investment brokers have recently updated their price targets on shares of MannKind Corporation (MNKD).

Most recent broker ratings

08/09/2016 – MannKind Corporation had its “underweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 0.1 price target on the stock.

05/10/2016 – MannKind Corporation had its “underperform” rating reiterated by analysts at RBC Capital. They now have a USD 0.2 price target on the stock.

04/28/2016 – MannKind Corporation had its “market perform” rating reiterated by analysts at JMP Securities.

03/30/2016 – MannKind Corporation had its “sell” rating reiterated by analysts at Goldman Sachs.

02/04/2016 – MannKind Corporation had its “underweight” rating reiterated by analysts at JP Morgan.

01/06/2016 – MannKind Corporation was upgraded to “buy” by analysts at Griffin Securities. They now have a USD 4 price target on the stock.

11/12/2015 – MannKind Corporation had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 9 price target on the stock.

05/11/2015 – MannKind Corporation had its “hold” rating reiterated by analysts at MLV & Co. They now have a USD 4 price target on the stock.

03/20/2015 – MannKind Corporation had its “neutral” rating reiterated by analysts at Zacks. They now have a USD 5.75 price target on the stock.

07/01/2014 – MannKind Corporation was downgraded to “hold” by analysts at Evercore ISI. They now have a USD 11 price target on the stock.

06/30/2014 – MannKind Corporation had its “outperform” rating reiterated by analysts at Brinson Patrick. They now have a USD 15 price target on the stock.

04/02/2014 – MannKind Corporation had its “market perform” rating reiterated by analysts at Cowen. They now have a USD 5 price target on the stock.

The share price of MannKind Corporation (MNKD) was down -1.92% during the last day of trading, with a day high of 0.47. 3954737 shares were traded during the last session.

The stock’s 50 day moving average is 0.65 and its 200 day moving average is 1.02. The stock’s market capitalization is 219.85M. MannKind Corporation has a 52-week low of 0.44 and a 52-week high of 3.79.

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company’s fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.